- Report
- October 2024
- 186 Pages
Global
From €3399EUR$3,545USD£2,840GBP
€3776EUR$3,939USD£3,155GBP
- Report
- April 2025
- 93 Pages
Global
From €5369EUR$5,600USD£4,486GBP
- Report
- February 2025
- 200 Pages
Global
From €4304EUR$4,490USD£3,597GBP
- Report
- May 2024
- 133 Pages
Global
From €6230EUR$6,499USD£5,206GBP
- Report
- May 2024
- 129 Pages
Global
From €6230EUR$6,499USD£5,206GBP
- Clinical Trials
- November 2024
- 80 Pages
Global
From €1917EUR$2,000USD£1,602GBP
- Report
- December 2024
- 65 Pages
Global
From €9582EUR$9,995USD£8,006GBP
- Report
- August 2020
- 112 Pages
Global
From €4074EUR$4,250USD£3,404GBP
- Report
- April 2023
- 111 Pages
Global
From €3500EUR$3,911USD£3,027GBP
- Report
- December 2023
- 62 Pages
Global
From €9582EUR$9,995USD£8,006GBP
- Report
- February 2024
- 25 Pages
Global
€16441EUR$17,150USD£13,737GBP
- Report
- April 2025
- 50 Pages
Global
From €2540EUR$2,650USD£2,123GBP

Febuxostat is a medication used to treat hyperuricemia, a condition in which the body produces too much uric acid. It is used to reduce the risk of gout flares and to prevent the formation of kidney stones. Febuxostat is a xanthine oxidase inhibitor, which works by blocking the enzyme that produces uric acid. It is used in combination with lifestyle changes, such as reducing alcohol consumption and avoiding certain foods, to reduce the risk of gout flares.
Febuxostat is a part of the immune disorders drugs market, which includes medications used to treat a variety of conditions related to the immune system. These drugs are used to treat autoimmune diseases, such as rheumatoid arthritis, lupus, and psoriasis, as well as allergies and asthma. They can also be used to treat certain types of cancer.
Companies in the Febuxostat market include AstraZeneca, Merck, Pfizer, and Takeda Pharmaceuticals. Show Less Read more